|
|
Volumn 364, Issue 9445, 2004, Pages 1577-1580
|
|
Should rosuvastatin be withdrawn from the market? [1] (multiple letters)
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ATORVASTATIN;
CERIVASTATIN;
FIBRIC ACID DERIVATIVE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LEVOTHYROXINE;
PRAVASTATIN;
ROSUVASTATIN;
SIMVASTATIN;
FLUOROBENZENE;
HYPOCHOLESTEROLEMIC AGENT;
PYRIMIDINE DERIVATIVE;
SULFONAMIDE;
ACUTE KIDNEY FAILURE;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DISEASE PREDISPOSITION;
DOSE RESPONSE;
DRUG CONTRAINDICATION;
DRUG EFFICACY;
DRUG INDICATION;
DRUG MARKETING;
DRUG POTENCY;
DRUG SAFETY;
DRUG SURVEILLANCE PROGRAM;
DRUG WITHDRAWAL;
DYSLIPIDEMIA;
HEMATURIA;
HUMAN;
KIDNEY TUBULE DISORDER;
KIDNEY TUBULE NECROSIS;
LETTER;
POSTMARKETING SURVEILLANCE;
PRESCRIPTION;
PRIORITY JOURNAL;
PROTEINURIA;
RHABDOMYOLYSIS;
RISK ASSESSMENT;
TREATMENT OUTCOME;
TREATMENT PLANNING;
DRUG APPROVAL;
FOOD AND DRUG ADMINISTRATION;
NOTE;
UNITED STATES;
DRUG UTILIZATION;
NETHERLANDS;
ANTICHOLESTEREMIC AGENTS;
DRUG APPROVAL;
FLUOROBENZENES;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
PYRIMIDINES;
SULFONAMIDES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
DRUG UTILIZATION;
NETHERLANDS;
PRODUCT SURVEILLANCE, POSTMARKETING;
|
|
EID: 7544249272
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(04)17301-7 Document Type: Letter |
|
Times cited : (18)
|
|
References (5)
|
